Catalyst Pharmaceuticals, Inc. (CPRX)
Automate Your Wheel Strategy on CPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including CPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CPRX
- Rev/Share 4.4014
- Book/Share 6.5388
- PB 3.8784
- Debt/Equity 0.0039
- CurrentRatio 6.1417
- ROIC 0.2215
- MktCap 3093286000.0
- FreeCF/Share 2.2027
- PFCF 11.5607
- PE 15.6095
- Debt/Assets 0.0034
- DivYield 0
- ROE 0.2828
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 2
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CPRX | Robert W. Baird | -- | Outperform | -- | $28 | Feb. 4, 2025 |
News
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
CPRX or NBIX: Which Is the Better Value Stock Right Now?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attractive to value investors?
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's Why
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career
Read More
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joel Beatty - Baird Charles Duncan - Cantor Fitzgerald Rohan Matur - Oppenheimer & Co. Inc. Jason Gerberry - …
Read More
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Read More
Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago.
Read More
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada.
Read More
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
Read More
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Read More
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Positive
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “managed and gradual” revenue decline.
Read More
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Published: February 27, 2025 by: The Motley Fool
Sentiment: Positive
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.
Read More
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Read More
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025.
Read More
About Catalyst Pharmaceuticals, Inc. (CPRX)
- IPO Date 2006-11-08
- Website https://www.catalystpharma.com
- Industry Biotechnology
- CEO Mr. Richard John Daly M.B.A.
- Employees 181